Open- | Close- |
Vol / Avg.0 / 777.856K | Mkt Cap51.014M |
Day Range- - - | 52 Wk Range0.945 - 3.170 |
Immunic Stock (NASDAQ: IMUX) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.0 / 777.856K | Mkt Cap51.014M |
Day Range- - - | 52 Wk Range0.945 - 3.170 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-10-10 | Wedbush | Andreas Argyrides | Maintains | OutperformOutperform | Raises | 5.00 | 7.00 |
2023-07-27 | Wedbush | Andreas Argyrides | Reiterates | OutperformOutperform | Maintains | - | 5.00 |
2023-01-31 | Wedbush | Andreas Argyrides | Assumes | Outperform | Announces | - | 5.00 |
2022-10-21 | SVB Leerink | Thomas Smith | Downgrades | OutperformMarket Perform | Lowers | 9.00 | 5.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
IMUX | Immunic | 0% | 51M |
SYRS | Syros Pharmaceuticals | 13.51% | 61.9M |
ESLA | Estrella Immunopharma | -0.67% | 52.1M |
ACXP | Acurx Pharmaceuticals | 1.67% | 50.4M |
ALGS | Aligos Therapeutics | 1.9% | 53.1M |
You can purchase shares of Immunic (NASDAQ: IMUX) through any online brokerage.
Other companies in Immunic’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Estrella Immunopharma (NASDAQ:ESLA), Acurx Pharmaceuticals (NASDAQ:ACXP), Aligos Therapeutics (NASDAQ:ALGS) and Elicio Therapeutics (NASDAQ:ELTX).
The latest price target for Immunic (NASDAQ: IMUX) was reported by Wedbush on Tuesday, October 10, 2023. The analyst firm set a price target for 7.00 expecting IMUX to rise to within 12 months (a possible 519.47% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Immunic (NASDAQ: IMUX) is $1.13 last updated November 28, 2023 at 10:00 PM UTC.
There is no dividend information for Immunic.
Immunic’s FY earnings are confirmed for Thursday, February 22, 2024.
There is no upcoming split for Immunic.
Immunic is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.